Q1 Results Show Reduced Loss, Increased Cash Amid Nasdaq Delisting

summarizeSummary

Reviva Pharmaceuticals reported Q1 2026 financial results showing a reduced net loss and a significant increase in cash to $22.2 million, providing a crucial operational runway as the company confirms its delisting from Nasdaq to the OTCQB Venture Market.

check_boxKey Events

• Nasdaq Delisting Confirmed

  The company's common stock will transition from Nasdaq to the OTCQB Venture Market on May 14, 2026, due to non-compliance with listing standards.

• Reduced Net Loss

  Reported a net loss of $3.2 million for Q1 2026, a 50% reduction compared to $6.4 million in Q1 2025.

• Increased Cash Runway

  Cash and cash equivalents rose to $22.2 million as of March 31, 2026, up from $14.4 million at year-end 2025, primarily due to a $10.0 million public offering completed in March.

• Phase 3 Trial Update

  Patient enrollment for the RECOVER-2 registrational Phase 3 trial for brilaroxazine is expected to begin in Q3 2026.

auto_awesomeAnalysis

This 8-K provides Q1 2026 financial results and confirms the company's delisting from Nasdaq. While the delisting is a significant negative event, the financial report shows a substantial increase in cash to $22.2 million and a reduced net loss, which is critical for the company's operational runway, especially given its prior "going concern" warning. This improved liquidity provides a lifeline as the company transitions to the OTCQB market and continues its clinical development programs, including the upcoming Phase 3 trial for brilaroxazine.